<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00200343</url>
  </required_header>
  <id_info>
    <org_study_id>MT711-01</org_study_id>
    <nct_id>NCT00200343</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C</brief_title>
  <official_title>A 24-week Multicenter Double-blind Control Trial With Ursodeoxycholic Acid in Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      This study is a 24-week multicenter, randomized, double-blind control trial with
      ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary
      objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day
      to that of 150mg/day and the safety of UDCA treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 24-week multicenter, randomized, double-blind control trial with
      ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary
      objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day
      to that of 150mg/day and the safety of UDCA treatment. The primary endpoint was percent
      changes of serum alanine aminotransferase(ALT) levels at 24-week of administration compared
      to pre-administration levels and secondary endpoints, serum aspartate aminotransferase(AST)
      and gamma-glutamyltranspeptidase(gamma-GTP) levels. Further, changes of bile acid composition
      and HCV-RNA levels at 24-week of administration were examined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alanine Aminotransferase at Baseline</measure>
    <time_frame>0 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change of Alanine Aminotransferase From Baseline at Week 24</measure>
    <time_frame>24 weeks (from baseline to Week 24)</time_frame>
    <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase at Baseline</measure>
    <time_frame>0 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Aspartate Aminotransferase From Baseline at Week 24</measure>
    <time_frame>24 weeks (from baseline to Week 24)</time_frame>
    <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl Transpeptidase at Baseline</measure>
    <time_frame>0 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change of Gamma-glutamyl Transpeptidase From Baseline at Week 24</measure>
    <time_frame>24 weeks (from baseline to Week 24)</time_frame>
    <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">596</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid 150mg / day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid 600mg / day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid 900mg / day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid 150mg / day</intervention_name>
    <description>Ursodeoxycholic acid, 150mg/ day, three times a day at meals</description>
    <arm_group_label>Ursodeoxycholic acid 150mg / day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid 600mg / day</intervention_name>
    <description>Ursodeoxycholic acid, 600mg/ day, three times a day at meals</description>
    <arm_group_label>Ursodeoxycholic acid 600mg / day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic acid 900mg / day</intervention_name>
    <description>Ursodeoxycholic acid, 900mg/ day, three times a day at meals</description>
    <arm_group_label>Ursodeoxycholic acid 900mg / day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must have a clinical diagnosis to apply the conservative medication for
             chronic hepatitis C.

          2. Serum alanine aminotransferase levels measured at 4-week before the initiation of
             treatment must be over 61 IU/mL.

          3. Subject's age must be 20 years or older.

        Exclusion Criteria:

          1. Subject who received a treatment of antiviral agents (interferon) within 20 weeks
             before the start of 8-week observation period

          2. Subject who received a treatment of corticosteroids, immunosuppressive drugs,
             glycyrrhizic acid, cholestyramine or other drugs which could interfere with hepatic
             function during 8-week observation period.

          3. Subject with decompensated cirrhosis

          4. Subject infecting with other hepatic virus

          5. Subject receiving a treatment for autoimmune disease, alcohol or drug-induced hepatic
             disorder, neoplasia, hepato-cholangiolar disease, fulminant hepatitis or peptic ulcer

          6. Subject who require hospitalization for complications of the heart, kidney or pancreas

          7. Pregnancy

          8. Alcoholics

          9. Alcohol intake more than 27 ml/day

         10. Subject who involved in other clinical trial within 4 weeks before the start of
             observation period

         11. Subject with a history of sensitivity to ursodeoxycholic acid or bile acid-products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masao Omata, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gastroenterology, University of Tokyo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, University of Tokyo</name>
      <address>
        <city>hongo, bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H; Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut. 2007 Dec;56(12):1747-53. Epub 2007 Jun 15.</citation>
    <PMID>17573387</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>August 17, 2011</results_first_submitted>
  <results_first_submitted_qc>September 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2011</results_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2012</last_update_posted>
  <keyword>Chronic hepatitis C, Ursodeoxycholic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>150mg / Day</title>
          <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
        </group>
        <group group_id="P2">
          <title>600mg / Day</title>
          <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
        </group>
        <group group_id="P3">
          <title>900mg / Day</title>
          <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>150mg / Day</title>
          <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
        </group>
        <group group_id="B2">
          <title>600mg / Day</title>
          <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
        </group>
        <group group_id="B3">
          <title>900mg / Day</title>
          <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="195"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="193"/>
            <count group_id="B4" value="586"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>10 patients were excluded from analysis population due to luck of sufficient data.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" spread="12.2"/>
                    <measurement group_id="B2" value="57.7" spread="12.0"/>
                    <measurement group_id="B3" value="59.8" spread="10.1"/>
                    <measurement group_id="B4" value="58.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alanine Aminotransferase at Baseline</title>
        <time_frame>0 week</time_frame>
        <population>10 patients were excluded from analysis population due to luck of sufficient data.</population>
        <group_list>
          <group group_id="O1">
            <title>150mg / Day</title>
            <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
          </group>
          <group group_id="O2">
            <title>600mg / Day</title>
            <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
          </group>
          <group group_id="O3">
            <title>900mg / Day</title>
            <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase at Baseline</title>
          <population>10 patients were excluded from analysis population due to luck of sufficient data.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.2" spread="49.7"/>
                    <measurement group_id="O2" value="106.3" spread="59.4"/>
                    <measurement group_id="O3" value="110.6" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase at Baseline</title>
        <time_frame>0 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mg / Day</title>
            <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
          </group>
          <group group_id="O2">
            <title>600mg / Day</title>
            <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
          </group>
          <group group_id="O3">
            <title>900mg / Day</title>
            <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase at Baseline</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" spread="39.1"/>
                    <measurement group_id="O2" value="82.4" spread="41.8"/>
                    <measurement group_id="O3" value="85.2" spread="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Aspartate Aminotransferase From Baseline at Week 24</title>
        <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
        <time_frame>24 weeks (from baseline to Week 24)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mg / Day</title>
            <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
          </group>
          <group group_id="O2">
            <title>600mg / Day</title>
            <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
          </group>
          <group group_id="O3">
            <title>900mg / Day</title>
            <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Aspartate Aminotransferase From Baseline at Week 24</title>
          <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
          <units>Percentage of change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="197"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" lower_limit="-74.2" upper_limit="347.2"/>
                    <measurement group_id="O2" value="-25.0" lower_limit="-82.7" upper_limit="72.5"/>
                    <measurement group_id="O3" value="-29.8" lower_limit="-79.0" upper_limit="1026.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gamma-glutamyl Transpeptidase at Baseline</title>
        <time_frame>0 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mg / Day</title>
            <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
          </group>
          <group group_id="O2">
            <title>600mg / Day</title>
            <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
          </group>
          <group group_id="O3">
            <title>900mg / Day</title>
            <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
          </group>
        </group_list>
        <measure>
          <title>Gamma-glutamyl Transpeptidase at Baseline</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="73.0"/>
                    <measurement group_id="O2" value="82.4" spread="62.2"/>
                    <measurement group_id="O3" value="85.9" spread="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change of Alanine Aminotransferase From Baseline at Week 24</title>
        <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
        <time_frame>24 weeks (from baseline to Week 24)</time_frame>
        <population>percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</population>
        <group_list>
          <group group_id="O1">
            <title>150mg / Day</title>
            <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
          </group>
          <group group_id="O2">
            <title>600mg / Day</title>
            <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
          </group>
          <group group_id="O3">
            <title>900mg / Day</title>
            <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Alanine Aminotransferase From Baseline at Week 24</title>
          <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
          <population>percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</population>
          <units>Percentage of change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" lower_limit="-80.7" upper_limit="375.9"/>
                    <measurement group_id="O2" value="-29.2" lower_limit="-88.3" upper_limit="95.2"/>
                    <measurement group_id="O3" value="-36.2" lower_limit="-81.4" upper_limit="1696.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change of Gamma-glutamyl Transpeptidase From Baseline at Week 24</title>
        <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
        <time_frame>24 weeks (from baseline to Week 24)</time_frame>
        <population>percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</population>
        <group_list>
          <group group_id="O1">
            <title>150mg / Day</title>
            <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
          </group>
          <group group_id="O2">
            <title>600mg / Day</title>
            <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
          </group>
          <group group_id="O3">
            <title>900mg / Day</title>
            <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change of Gamma-glutamyl Transpeptidase From Baseline at Week 24</title>
          <description>Percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</description>
          <population>percentage change=[(measured value at Week 24 - measured value at baseline)/measured value at baseline]*100</population>
          <units>Percentage of change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.4" lower_limit="-74.6" upper_limit="145.9"/>
                    <measurement group_id="O2" value="-41.0" lower_limit="-81.1" upper_limit="153.1"/>
                    <measurement group_id="O3" value="-50.0" lower_limit="-80.1" upper_limit="213.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The reported adverse event data were collected for 24 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>150mg / Day</title>
          <description>ursodeoxycholic acid, 150mg/day, three times a day at meals</description>
        </group>
        <group group_id="E2">
          <title>600mg / Day</title>
          <description>ursodeoxycholic acid, 600mg/day, three times a day at meals</description>
        </group>
        <group group_id="E3">
          <title>900mg / Day</title>
          <description>ursodeoxycholic acid, 900mg/day, three times a day at meals</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA ver.6.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Inguinal hernia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Renal neoplasm NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lung cancer stage unspecified (excl metastatic tumours to lung)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA ver.6.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials, Information Desk</name_or_title>
      <organization>Mitsubishi Tanabe Pharma Corporation</organization>
      <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

